Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fruquintinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fruquintinib overview
Fruquintinib (Elunate) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Elunate is indicated for the treatment of metastatic colorectal cancer patients, who have failed at least two prior systemic antineoplastic therapies including fluoropyrimidine, oxaliplatin and irinotecan, with or without prior use of anti-vascular endothelial growth factor or anti-epidermal growth factor receptor therapies.
Fruquintinib (HMPL-013) is under development for the treatment of locally advanced rectal cancer, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma, angiosarcoma, soft tissue sarcoma, advanced or metastatic triple negative breast cancer, HER2 negative breast cancer, metastatic colorectal adenocarcinoma, metastatic renal cell carcinoma, metastatic biliary tract adenocarcinoma, advanced solid tumor including gastric cancer, gastroesophageal junction adenocarcinoma and advanced non squamous non small cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, breast cancer, advanced or recurrent/metastatic pancreatic adenocarcinoma and meningioma. It is administered orally. It was also under development for hepatocellular carcinoma and thymic cancer.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a global pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East, and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Fruquintinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
